Mode of action analysis for liver tumors from oral 1,4-dioxane exposures and evidence-based dose response assessment

Regulatory Toxicology and Pharmacology

Volumn 68, Issue 3, 2014, Pages 387-401

  Dourson, Michael ^a   Reichard, John ^a   Nance, Patricia ^a   Burleigh Flayer, Heather ^b   Parker, Ann ^a   Vincent, Melissa ^a   McConnell, Ernest E ^c  

^a Toxicology Excellence for Risk Assessment   (United States)

^b PPG INDUSTRIES   (United States)

^c ToxPath Inc   (United States)

Author keywords

Dioxane; Dose response assessment; Liver hyperplasia; Liver toxicity; Maximum contaminant level goal (MCLG); Mode of action; Oral reference dose (RfD); Toxicology

Indexed keywords

DIOXANE; DRINKING WATER; GLYCOGEN; 1,4-DIOXANE; DIOXANE DERIVATIVE; SOLVENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CHEMICAL CARCINOGENESIS; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOTOXICITY; DNA REPAIR; DNA SYNTHESIS; ENVIRONMENTAL EXPOSURE; FATTY LIVER; FEMALE; HEPATITIS; INCIDENCE; KUPFFER CELL; LIVER HYPERPLASIA; LIVER NECROSIS; LIVER TOXICITY; LIVER TUMOR; MALE; MAXIMUM CONTAMINANT LEVEL GOAL; MODE OF ACTION ANALYSIS; MOUSE; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; REFERENCE DOSE; REGENERATION; TOXICITY TESTING; TRANSCRIPTION INITIATION; ANIMAL; BIOLOGICAL MODEL; CHEMICALLY INDUCED; DOSE RESPONSE; DRUG EFFECTS; HYPERPLASIA; LIVER; ORAL DRUG ADMINISTRATION; PATHOLOGY; RISK ASSESSMENT; STANDARDS; TOXICITY;

ADMINISTRATION, ORAL; ANIMALS; DIOXANES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRINKING WATER; FEMALE; HYPERPLASIA; LIVER; LIVER NEOPLASMS; MALE; MICE; MODELS, BIOLOGICAL; RISK ASSESSMENT; SOLVENTS;

EID: 84896712761     PISSN: 02732300     EISSN: 10960295     Source Type: Journal    
DOI: 10.1016/j.yrtph.2014.01.011     Document Type: Article

References (48)

1. Argus M.F., Arcos J.C., Hoch-Ligeti C. Studies on the carcinogenic activity of protein-denaturing agents: hepatocarcinogenicity of dioxane. J. Natl. Cancer Inst. 1965, 35:949-958.
2. Argus M.F., Sohal R.S., Bryant G.M., Hoch-Ligeti C., Arcos J.C. Dose-response and ultrastructural alterations in dioxane carcinogenesis. Eur. J. Cancer 1973, 9:237-243.
3. ATSDR (Agency for Toxic Substances and Disease Registry), 2007. Toxicological Profile for 1,4-Dioxane. Draft for Public Comment. Atlanta, GA. Available at: http://www.atsdr.cdc.gov/toxprofiles/tp187.pdf.
4. Barber H. Haemorrhagic nephritis and necrosis of the liver from dioxin poisoning. Guy's Hosp. Rep. 1934, 84:267-280.
5. Bull R., Robinson M., Laurie R. Association of carcinoma yield with early papilloma development in SENCAR mice. Environ. Health Perspect. 1986, 68:11-17.
6. Dourson M.L., Knauf L.A., Swartout J.C. On reference dose (RfD) and its underlying toxicity data base. Toxicol. Ind. Health 1992, 8(3):171-189.
7. Dourson M.L., Hertzberg R., Allen B., Haber L.T., Parker A., Kroner O., Maier A., Kohrman M. Evidence-based dose-response assessment for thyroid tumorigenesis from acrylamide. Regul. Toxicol. Pharmacol. 2008, 52:264-289.
8. Ernstgard L., Iregren A., Sjogren B., Johanson G. Acute effects of exposure to vapours of dioxane in humans. Hum. Exp. Toxicol. 2006, 25:723-729.
9. Fairley A., Linton E., Ford-Moore A. The toxicity to animals of 1:4 dioxane. J. Hyg. 1934, 34:486-501.
10. Goldsworthy T., Monticello T., Morgan K., Bermudez E., Wilson D., Jäckh R., Butterworth B.E. Examination of potential mechanisms of carcinogenicity of 1,4-dioxane in rat nasal epithelial cells and hepatocytes. Arch. Toxicol. 1991, 65(1):1-9.
11. Haber L.T., Maier A., Kroner O.L., Kohrman M.J. Assessment of human relevance and mode of action for tunica vaginalis mesotheliomas resulting from oral exposure to acrylamide. Regul. Toxicol. Pharmacol. 2009, 53(2):134-149.
12. Health Canada Screening Assessment for the Challenge of 1,4-Dioxane 2010, Environment Canada, Health Canada, Ottawa, ON, Canada.
13. IPCS (International Programme on Chemical Safety), 2005. Chemical-specific adjustment factors for interspecies differences and human variability: guidance document for use of data in dose/concentration-response assessment. Geneva Switzerland. Available at: http://www.who.int/ipcs/methods/harmonization/areas/uncertainty/en/index.html.
14. Johnstone R. Death due to dioxane?. AMA Arch. Ind. Health 1959, 20:445-447.
15. Kano H., Umeda Y., Saito M., Senoh H., Ohbayashi H., Aiso S., Yamazaki K., Nagano K., Fukushima S. Thirteen-week oral toxicity of 1,4-dioxane in rats and mice. J. Toxicol. Sci. 2008, 33(2):141-153.
16. Kano H., Umeda Y., Kasai T., Sasaki T., Matsumoto M., Yamazaki K., Nagano K., Arito H., Fukushima S. Carcinogenicity studies of 1,4-dioxane administered in drinking-water to rats and mice for 2years. Food Chem. Toxicol. 2009, 47(11):2776-2784.
17. Kasai T., Saito M., Senoh H., Umeda Y., Aiso S., Ohbayashi H., Nishizawa T., Nagano K., Fukushima S. Thirteen-week inhalation toxicity study of 1,4-dioxane in rats. Inhal. Toxicol. 2008, 20:961-970.
18. Kasai T., Kano H., Umeda Y., Sasaki T., Ikawa N., Nishizawa T., Nagano K., Arito H., Nagashima H., Fukushima S. Two-year inhalation study of carcinogenicity and chronic toxicity of 1,4-dioxane in male rats. Inhal. Toxicol. 2009, 21(11):889-897.
19. King M., Shefner A., Bates R. Carcinogenesis bioassay of chlorinated dibenzodioxins and related chemicals. Environ. Health Perspect. 1973, 5:163-170.
20. Kociba, R.J., Torkelson, T.R., Clashman, A., McCollister, S., Gehring, P.J., 1971. Continuous exposure of Sherman rats to various concentrations of 1,4-dioxane in drinking water for two years. The Dow Chemical Company, Biochemical Research Laboratory. 7901059. March 10.
21. Kociba R.J., McCollister S.B., Park C., Torkelson T.R., Gehring P.J. 1,4-Dioxane. I. Results of a 2-year ingestion study in rats. Toxicol. Appl. Pharmacol. 1974, 30:275-286.
22. Kociba, R.J., Torkelson, T.R., Young, J.D., Gehring, P.J., (1975). 1,4-Dioxane: Correlation of the results of chronic ingestion and inhalation studies with its dose-dependent fate in rats. In Proceedings of the 6th Annual Conference on Environmental Toxicology (pp. 345-354). Wright-Patterson Air Force Base, OH: Wright-Patterson Air Force Base, Air Force Systems Command, Aerospace Medical Division, Aerospace Medical Research Laboratory.
23. Koissi N., Shah N.H., Ginevan B., Eck W.S., Roebuck B.D., Fishbein J.C. Lactone metabolite common to the carcinogens dioxane, diethylene glycol, and N-nitrosomorpholine: aqueous chemistry and failure to mediate liver carcinogenesis in the F344 rat. Chem. Res. Toxicol. 2012, 25(5):1022-1028.
24. Lundberg I., Hogberg J., Kronevi T., Holmberg B. Three industrial solvents investigated for tumor promoting activity in the rat liver. Cancer Lett. 1987, 36:29-33.
25. McConnell, G., 2011. Personal communication between Michael Dourson and Gene McConnell, October, 2011.
26. McConnell, G., 2013. Report on the review of liver slides from the National Cancer Institute's Bioassay of 1,4-Dioxane for Possible Carcinogenicity Conducted in 1978 (NCI, 1978). Submitted to Toxicology Excellence for Risk Assessment. January/March 2013.
27. Meek M.E., Bucher J.R., Cohen S.M., Dellarco V., Hill R.N., Lehman-McKeeman L.D., Longfellow D.G., Pastoor T., Seed J., Patton D.E. A framework for human relevance analysis of information on carcinogenic modes of action. Crit. Rev. Toxicol. 2003, 33(6):591-653.
28. Miyagawa M., Shirotori T., Tsuchitani M., Yoshikawa K. Repeat-assessment of 1,4-dioxane in a rat-hepatocyte replicative DNA synthesis (RDS) test: evidence for stimulus of hepatocyte proliferation. Exp. Toxicol. Pathol. 1999, 51:555-558.
29. Nannelli A., De Rubertis A., Longo V., Gervasi P. Effects of dioxane on cytochrome P450 enzymes in liver, kidney, lung and nasal mucosa of rat. Arch. Toxicol. 2005, 79:74-82.
30. 1,4-Dioxane Priority Existing Chemical No. 7 Full Public Report. National Industrial Chemicals Notification and Assessment Scheme: 1978, NICNAS (National Industrial Chemicals Notification and Assessment Scheme), NICNAS, Canberra, Australia, 78-1330.
31. Bioassay of 1,4-Dioxane for possible Carcinogenicity. Carcinogenesis Testing Program, Division of Cancer Cause and Prevention, National Cancer Institute 1978, NCI (National Cancer Institute), NIH, Bethesda, MD, 78-1330.
32. Voluntary Children's Chemical Evaluation Program (VCCEP). Tiers 1, 2 and 3. Pilot Submission for 1,4-Dioxane 2007, Sapphire Group, Sponsor: Ferro Corporation, Cleveland, Ohio.
33. Silverman L., Schulte H., First M. Further studies on sensory response to certain industrial solvent vapors. J. Ind. Hyg. Toxicol. 1946, 28:262-266.
34. Stott W., Quast J., Watanabe P. Differentiation of the mechanisms of oncogenicity of 1,4-dioxane and 1,3-hexachlorobutadiene in the rat. Toxicol. Appl. Pharmacol. 1981, 60:287-300.
35. Sweeney L.M., Thrall K.D., Poet T.S., Corley R.A., Weber T.J., Locey B.J., Clarkson J., Sager S., Gargas M.L. Physiologically based pharmacokinetic modeling of 1,4-dioxane in rats, mice, and humans. Toxicol. Sci. 2008, 101(1):32-50.
36. Theiss A., Tress E., Fleig I. Industrial-medical investigation results in the case of workers exposed to dioxane. Arbeitsmedizin, Socialmedizin, Umweltmedizin 1976, 11:35-46.
37. Uno Y., Takasawa H., Miyagawa M., Inoue Y., Murata T., Yoshikawa K. An in vivo-in vitro replicative DNA synthesis (RDS) test using rat hepatocytes as an early prediction assay for nongenotoxic hepatocarcinogens screening of 22 known positives and 25 noncarcinogens. Mutat. Res. 1994, 320:189-205.
38. US EPA (US Environmental Protection Agency), 2000. Methodology for Deriving Ambient Water Quality Criteria for the Protection of Human Health. Office of Water, Washington, D.C. EPA/822/B-00/004.
39. US EPA (US Environmental Protection Agency), 2002. A Review of the Reference Dose (RfD) and Reference Concentration (RfC) Processes. Risk Assessment Forum. Washington, D.C. EPA/630/P-02/002F, December.
40. US EPA (US Environmental Protection Agency), 2005. Guidelines for Carcinogen Risk Assessment. Washington D.C. EPA/630/P-03/001B.
41. US EPA (US Environmental Protection Agency), 2013. Toxicological Review of 1,4-Dioxane (with Inhalation Update). Washington, D.C. EPA/635/R-11/003F.
42. US EPA (United States Environmental Protection Agency), 2012. Benchmark dose technical guidance document. Final Draft. EPA/100/R-12/001, June 2012. Available at: http://www.epa.gov/raf/publications/benchmarkdose.htm.
43. Wirth W., Klimmer O. On the toxicology of organic solvents. 1,4 dioxane (diethylene dioxide). Archiv fuer Gewerbepathologie und Gewerbehygiene 1936, 17:192-206.
44. Woo Y.-T., Argus M., Arcos J. Tissue and subcellular distribution of 3H-dioxane in the rat and apparent lack of microsome-catalyzed covalent binding in the target tissue. Life Sci. 1977, 21:1447-1456.
45. Yamazaki, K., Ohno, H., Asakura, M., Narumi, A., Ohbayashi, H., Fujita, H., Ohnishi, M., Katagiri, T., Senoh, H., Yamanouchi, K., Nakayama, E., Yamamoto, S., Noguchi, T., Nagano, K., Enomoto, M., Sakabe, H., 1994. Two-year toxicological and carcinogenesis studies of 1,4-dioxane in F344 rats and BDF1 mice. In: K. Sumino, S. Sato, N.G. Shinkokai, (Eds.), Proceedings: Second Asia-Pacific Symposium on Environmental and Occupational Health 22-24 July 1993. Kobe University School of Medicine, International Center for Medical Research. Kobe, Japan, pp. 193-198.
46. Yant W., Schrenk H., Waite C., Patty F. Acute response of guinea pigs to vapors of some new commercial organic compounds: VI. Dioxan. Public Health Rep. 1930, 45:2023-2032.
47. Young J., Braun W., Gehring P. The dose-dependent fate of 1,4-dioxane in rats. J. Environ. Pathol. Toxicol. 1978, 2:263-282.
48. Young J., Braun W., Rampy L., Chenoweth M., Blau G. Pharmacokinetics of 1,4-dioxane in humans. J. Toxicol. Environ. Health 1977, 3:507-520.